Kirk Eddleman, MD
Rheumatology · Oxford, MSNPI 1821209784
Payments from drug & device makers
Across 1,227 payments — averaging $469.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$258K
- AbbVie$139K
- UCB, Inc.$84K
- Bristol Myers Squibb$38K
- Lilly USA, LLC$29K
- Regeneron Healthcare Solutions, Inc.$10K
- plus $17K from 21 others
What the payments were for
- Consulting fees$22,6994%
- Speaking & faculty fees$509,34588%
- Travel & lodging$23,8304%
- Food & beverage$19,3743%
- Education$2970%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 406 | $257,862 |
| AbbVie | 311 | $139,056 |
| UCB, Inc. | 148 | $83,502 |
| Bristol Myers Squibb | 60 | $37,966 |
| Lilly USA, LLC | 37 | $29,321 |
| Regeneron Healthcare Solutions, Inc. | 29 | $10,395 |
| Johnson & Johnson | 37 | $6,383 |
| GSK | 46 | $5,743 |
| Pfizer | 52 | $2,355 |
| Novartis | 35 | $1,069 |
| Sanofi | 1 | $662 |
| E.r. Squibb & Sons, L.L.C. | 10 | $185 |
| AstraZeneca(2 entities) | 9 | $169 |
| Aurinia Pharma U.S., Inc. | 7 | $165 |
| Boehringer Ingelheim | 9 | $151 |
| Mallinckrodt Hospital Products Inc. | 6 | $141 |
| Fresenius Kabi USA, LLC | 4 | $86 |
| Organon | 4 | $82 |
| Genentech USA, Inc. | 4 | $60 |
| ANI Pharmaceuticals, Inc. | 2 | $41 |
| Mylan Institutional Inc. | 2 | $35 |
| Sandoz | 2 | $32 |
| Hikma Pharmaceuticals USA | 2 | $27 |
| Radius Health, Inc. | 1 | $16 |
| Mallinckrodt Enterprises LLC | 1 | $16 |
| Sebela Pharmaceuticals Inc. | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$575,545 in reported general payments places this provider in the 95th percentile of 44 rheumatology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 206 | $1,449,345 |
| Enbrel SureclickEtanercept | 167 | $1,220,309 |
| RinvoqUpadacitinib | 185 | $1,127,544 |
| IlarisCanakinumab/Pf | 15 | $574,218 |
| Enbrel MiniEtanercept | 48 | $339,563 |
| Taltz AutoinjectorIxekizumab | 29 | $257,635 |
| Skyrizi PenRisankizumab-Rzaa | 12 | $234,200 |
| BenlystaBelimumab | 57 | $227,601 |
| Taltz Autoinjector (2 Pack)Ixekizumab | 18 | $225,893 |
| Actemra ActpenTocilizumab | 58 | $214,648 |
| KevzaraSarilumab | 37 | $149,923 |
| Xeljanz XrTofacitinib Citrate | 26 | $143,501 |
| OtezlaApremilast | 25 | $95,552 |
| EnbrelEtanercept | 11 | $77,938 |
| OrenciaAbatacept | 13 | $72,349 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $139,056 | $1,127,544185 claims |
| NovartisIlaris | $1,069 | $574,21815 claims |
| GSKBenlysta | $5,743 | $227,60157 claims |
| AmgenOtezla, Enbrel | $257,862 | $173,49136 claims |
| SanofiKevzara | $662 | $149,92337 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $185 | $72,34913 claims |
| Hikma Pharmaceuticals USAMitigare | $27 | $5,11814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 44 rheumatology providers in Mississippi.
Other rheumatology in Oxford
- Lauren HaywardOxford$17K
- Vikas MajithiaJackson$1.4M
- David WeissHattiesburg$597K
- Charles KingTupelo$404K
- Jason TaylorMadison$173K
- Matthew CarrollKeesler Afb$56K
- Neal ShparagoJackson$39K
- Seth ComptonMadison$22K
- Sharon HongFlowood$22K
- Nicole WaltonOcean Springs$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.